2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Melanoma
4
Carcinoma, Basal Cell
4
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Cisplatin
76
Radiotherapy
44
Cetuximab
40
pembrolizumab
39
Paclitaxel
34
Carboplatin
33
Docetaxel
30
Fluorouracil
25
Radiotherapy, Intensity-Modulated
23
Nivolumab
18
Drug Therapy
14
Radiation
12
Erlotinib Hydrochloride
9
cemiplimab
8
Magnetic Resonance Spectroscopy
8
Blood Specimen Collection
8
130-nm albumin-bound paclitaxel
8
durvalumab
7
atezolizumab
7
Cyclophosphamide
7
Afatinib
7
Surveys and Questionnaires
6
Surgical Procedures, Operative
6
Panitumumab
6
Leucovorin
6
Esophagectomy
6
Chemoradiotherapy
6
fludarabine
5
aldesleukin
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Squamous Cell
×
daromun
×
Clear all
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled